Latest News for: janus kinase 3

Edit

Rheumatoid Arthritis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Revenue, Statistics, Therapies, ...

GetNews 15 Apr 2025
OLUMIANT is an immunosuppressant that is indicated for use in inflammatory and autoimmune diseases, or in other terms, it is defined as a Janus kinase (JAK) inhibitor used to treat adults with ...
Edit

Ulcerative Colitis Market Set for Robust Growth Across the 7MM from USD 8.4 Billion in ...

GetNews 11 Apr 2025
The ulcerative colitis treatment market currently encompasses multiple therapeutic approaches, including aminosalicylates, corticosteroids, immunomodulators, biologic therapies, S1P modulators, and Janus kinase inhibitors ... Visit the ... Table of Contents.
Edit

Alopecia Areata Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, ...

GetNews 11 Apr 2025
It covers the Alopecia Areata pipeline drugs profiles, including clinical and nonclinical stage products ... Concert Pharmaceuticals. Concert Pharmaceuticals is developing deuruxolitinib (CTP-543), an oral inhibitor of Janus kinases JAK1 and JAK2 ... EQ101.
Edit

Chronic Hand Eczema Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | ...

GetNews 11 Apr 2025
The study evaluated Anzupgo® (delgocitinib) 20mg/g cream, a topical pan-Janus kinase (JAK) inhibitor, for the potential treatment of moderate to severe Chronic Hand Eczema (CHE) in Chinese ...
  • 1
×